Merck Inc. to market Lixiana (edoxaban)in Nordic and Eastern European countries- Daiichi Sankyo

Daiichi Sankyo Company, Limited announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group has granted exclusive rights to Merck & Co., Inc., to market the oral, once-daily anti-coagulant, Lixiana (edoxaban), in 13 European countries: Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Iceland, Norway, Poland, Romania, Slovakia, Slovenia and Sweden. DSE currently has no affiliated companies in these countries, so this agreement will contribute significantly to the growth of edoxaban in Europe.

The aforementioned 13 countries are subject to the marketing authorization of the oral, once-daily anti-coagulant edoxaban which was obtained from the European Commission last June. Sales will proceed as soon as MSD completes launch preparations.